Skip to main content

Posts

Showing posts with the label technical analysis

ORLY STOCK WRITE UP

ORLY (O'REILLY AUTOMOTIVE PARTS) P/E: 16.3 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: ASSETS-LIABILITIES: 2.06 SECTOR: RETAIL TRADE DIVIDEND: none ORLY is a chain of Auto Parts stores. The company's share price plunged almost 19% 7/5/17, after reporting a decline in its same-store sales numbers. A rapidly expanding company, ORLY has a disproportionate amount of debt on its balance sheet. In the last quarter, O'Reilly increased sales by almost 3%, while operating income decreased by almost 4%. However, the company did post an increase in EPS on a year-over-year basis by virtue of decreased taxation. Autozone has only 1% of the amount of cash as it does long-term debt. The company also reports that it has roughly twice as much assets as it does liabilities, with the majority of these holdings in inventory and property. Cash decreased from 4Q '16 to 1Q '17, coinciding with the rise in inventory, and property. O'Rei...

EXEL STOCK WRITE UP

EXEL (EXELISIS INC) P/E: 800 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $.31 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.24 DIVIDEND: none Exilixis is a pharmaceutical company specializing in cancer drugs. The company is up already over 60% YTD. It is heavily owned by the major institutions. In each of the last 4 quarters, EXEL has beat Wall Street expectations, according to Estimize. The last two quarters have been profitable, and the company has set its expectations for profitable quarters in the future. Previously, the company posted consistent losses. Revenue increased approximately 550% on a year-over-year basis, while collaborative revenue doubled. EXEL has partnerships with Roche and GlaxoSmithKline. Cabometyx, a rectal cancer drug, is its largest revenue source in the latest quarter and most recent drug launch for the company. Exelixis announced that their R&D budget decreased due to decreased costs in one of their drug s...

JWA STOCK WRITE UP

JWA (JOHN WILEY AND SONS) P/E: 31.4 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $.15 SECTOR: Consumer Services ASSETS-LIABILITIES: 3.29 DIVIDEND: 2.28% John Wiley and Sons is a company that provides research resources, online project management, and publishing services. The company is best known for its 'For Dummies' series, and reported after the bell 6/13/17. JWA beat EPS estimates by $.11. A close analysis of the earnings report released 6/13/17 shows EPS increased at a significantly higher rate than revenue. JWA significantly cut administrative costs, and revenue did increase, leading to a sizable increase in EPS. The company has a large share buyback and dividend program. While it has over three times as much assets on the book as it does liabilities, the company does not include long-term debt in its accounting for liabilities. JWA has approximately 15% as much cash as it does long-term debt. The company cut its long-term deb...

MHK STOCK WRITE UP

MHK (MOHAWK INDUSTRIES) P/E: 18.6 GAAP DILUTED EPS Y-O-Y GROWTH LAST QUARTER: $.44 SECTOR: CONSUMER DURABLES ASSETS-LIABILITIES: 2.312 DIVIDEND: none Mohawk industries is a stock you probably have not heard of, unless you are a DIY enthusiast or work in homebuilding. Mohawk is a supplier of carpet, wall tiles, and laminate. They have posted consistent revenue increases over the last 5 years. In 2016, the company spent a record amount on capital investing in order to continue the growth of its business, and plans to expand on that strategy in 2017. The company is dedicating itself to expansion of manufacturing capacity and development of new products, rather than acquisitions. This capital expenditure has not slowed the company's growth, however, as its operating income margin has also increased over the last 5 years. Jeffrey Lorberbaum, the company's CEO, is the son of the owners of a flooring company which was acquired by Mohawk. Lorberbaum...